Aspire Biopharma Holdings, Inc. (ASBP) vs China SXT Pharmaceuticals, Inc. (SXTC)

A side-by-side comparison of Aspire Biopharma Holdings, Inc. and China SXT Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ASBP

Aspire Biopharma Holdings, Inc.

$1M

$8.88HealthcareDelayed quote: Oct 6, 2026, 2:40 PM EDT

SXTC

China SXT Pharmaceuticals, Inc.

$723376

$1.35HealthcareDelayed quote: Oct 6, 2026, 2:40 PM EDT

Total return — ASBP vs SXTC

growth of $100 · dividends reinvested · last 4y

ASBP -99.9% (-84.3%/yr)SXTC -100.0% (-96.8%/yr)ASBP compounded faster over this window

Log scale — wide-divergence pair

ASBP SXTC

Metrics side by side

Total return (annualized)

Metric	ASBP	SXTC
Total return (1Y)	-98.04%	N/A
Total return CAGR (3Y)	-91.13%	N/A

SXTC is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full ASBP analysis Full SXTC analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.